| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |